Hi Mr Cod,
I thought that exact same thing and questioned Jon on this on 16/08. See my question below and his reply in capitals.
3- In relation to the ROW rights deal for Trof is the possible sale of the company at a later date a consideration when looking at who to partner with? I’d imagine it would be a little more difficult to find a potential acquirer if all the trof rights are sold. AS YOU KNOW I BELIEVE NNZ-2591 GLOBAL RIGHTS AND IN PARTICULAR US RIGHTS ARE THE MOST VALUABLE ASSET AND MUCH MORE ATTRACTIVE TO POTENTIAL ACQUIRERS THAN TROFINETIDE EX-US RIGHTS. HAVING SAID THAT WE ARE OF COURSE MINDFUL ABOUT THE FUTURE AS WELL AS THE PRESENT WHEN CONSIDERING OUR OPTIONS FOR ROW.
- Forums
- ASX - By Stock
- NEU
- Neuren Pharmaceuticals with Proactive at ASX Small and Mid-Cap Conference
Neuren Pharmaceuticals with Proactive at ASX Small and Mid-Cap Conference, page-12
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$12.61 |
Change
0.140(1.12%) |
Mkt cap ! $1.611B |
Open | High | Low | Value | Volume |
$12.45 | $12.62 | $12.22 | $2.973M | 237.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1257 | $12.52 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$12.62 | 1257 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1257 | 12.520 |
4 | 5178 | 12.510 |
3 | 1572 | 12.500 |
2 | 1634 | 12.490 |
1 | 2000 | 12.410 |
Price($) | Vol. | No. |
---|---|---|
12.620 | 1257 | 1 |
12.630 | 39 | 2 |
12.640 | 1257 | 1 |
12.680 | 400 | 1 |
12.750 | 1000 | 1 |
Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |